Skip to main content
Clinical Trials/NCT04491773
NCT04491773
Completed
Not Applicable

Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days for More Than 6 Months: a Single-centre Prospective-control

Federico II University1 site in 1 country54 target enrollmentNovember 1, 2019

Overview

Phase
Not Applicable
Intervention
Tadalafil 20 MG
Conditions
Erectile Dysfunction Following Radical Prostatectomy
Sponsor
Federico II University
Enrollment
54
Locations
1
Primary Endpoint
The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil for more than 6 months
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg for more than 6 months, using optical coherence tomography angiography.

Detailed Description

Tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection. This drug represents an treatment for erectile dysfunction in patients after radical prostatectomy. The optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. The study evaluates the changes in optical coherence tomography angiography features after the somministration of Tadalafil 20 mg orally for more than 6 months.

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
May 30, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Gilda Cennamo

Principal Investigator

Federico II University

Eligibility Criteria

Inclusion Criteria

  • age older than 45 years
  • diagnosis of erectile dysfunction due to surgery of radical prostatectomy
  • treatment-naïve with Tadalafil for erectile dysfunction for more than 6 months
  • absence of diabetes, heart diseases, hypertension
  • absence of drug intake
  • absence of vitreoretinal, vascular retinal diseases
  • absence of previous ocular surgery and congenital eye diseases.
  • absence of errors of refraction
  • absence of lens opacities
  • absence of low-quality OCT and OCTA images

Exclusion Criteria

  • age younger than 45 years
  • diagnosis of erectile dysfunction due to other causes
  • previous treatments before Tadalafil for erectile dysfunction
  • presence of diabetes, heart diseases, hypertension
  • drug intake
  • vitreoretinal and vascular retinal diseases
  • previous ocular surgery and congenital eye diseases
  • errors of refraction
  • lens opacities
  • low-quality OCT and OCTA images

Arms & Interventions

Patients undergoing Tadalafil

Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months

Intervention: Tadalafil 20 MG

Outcomes

Primary Outcomes

The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil for more than 6 months

Time Frame: More than 6 months

Changes in retinal and choriocapillary vessel density in patients after radical prostatectomy, undergoing Tadalafil 20 mg orally on alternate days for more than 6 months, using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillary vessel density

Study Sites (1)

Loading locations...

Similar Trials